Joel Michalski, MD
Internal Medicine · Omaha, NENPI 1437599248
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,128 of the $10,060 with a category attached, or 80.8%. 39 manufacturers reported payments, led by Gilead at 37.4% of the total. 2025 is the largest year on record at $4,235, more than ten times the $133 reported in 2021. Among internal medicine clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $127.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- AstraZeneca$4K
- Genentech USA, Inc.$1K
- Sanofi US Services Inc.$125
- AVEO Pharmaceuticals, Inc.$110
- Hologic Sales And Service, LLC$96
- plus $1K from 33 others
Across 239 payments — averaging $6798.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$572K
- Pfizer$254K
- Genmab A/s$246K
- AbbVie$160K
- Merck$149K
- Amgen$119K
- plus $125K from 3 others
What the payments were for
- Consulting fees$8,12881%
- Food & beverage$1,66317%
- Education$2693%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,060 in reported general payments places this provider in the 95th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 48 | $638,252 |
| Lenalidomide | 33 | $514,341 |
| AyvakitAvapritinib | 12 | $467,625 |
| RevlimidLenalidomide | 20 | $383,876 |
| LenvimaLenvatinib Mesylate | 16 | $381,550 |
| TagrissoOsimertinib Mesylate | 20 | $335,098 |
| TabrectaCapmatinib Hydrochloride | 14 | $312,422 |
| XtandiEnzalutamide | 20 | $287,412 |
| JakafiRuxolitinib Phosphate | 12 | $210,876 |
| CalquenceAcalabrutinib Maleate | 12 | $184,846 |
| XareltoRivaroxaban | 51 | $33,397 |
| VenclextaVenetoclax | 18 | $26,295 |
| EliquisApixaban | 42 | $24,121 |
| Imatinib Mesylate | 27 | $19,771 |
| Abiraterone Acetate | 16 | $16,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $65 | $638,25248 claims |
| AstraZenecaTagrisso, Calquence | $3,648 | $519,94532 claims |
| Blueprint Medicines CorporationAyvakit | $32 | $467,62512 claims |
| Bristol Myers SquibbRevlimid | $18 | $383,87620 claims |
| Eisai Inc.Lenvima | $16 | $381,55016 claims |
| NovartisTabrecta | $64 | $312,42214 claims |
| Johnson & JohnsonXarelto | $20 | $33,39751 claims |
| AbbVieVenclexta | $86 | $26,29518 claims |
| PfizerEliquis | $56 | $24,12142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Omaha
- Brian BoerOmaha$142K
- Adam BurdorfOmaha$29K
- David SharpOmaha$26K
- David ShinOmaha$26K
- Nikhil JaganOmaha$20K
- Clayton SchroederOmaha$14K
- Ali NayfehOmaha$12K
- Kirtibala GuptaOmaha$12K
- Chad VokounOmaha$11K
- Sean McMillanOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.